For possible common duct stones, do intraop cholangiogram before ERCP: study
For possible common duct stones, do intraop cholangiogram before ERCP: study
By James E. Barone MD
NEW YORK (Reuters Health) - Patients at intermediate risk
for common bile duct stones who had cholangiography during
cholecystectomy - with endoscopic retrograde
cholangiopancreatography (ERCP) afterward only if needed - did
just as well as those who had ERCP before cholecystectomy,
researchers say.
"This strategy decreases the length of stay, the need for
endoscopic and radiologic investigations and, indirectly, the
costs," said surgeons Dr. Pouya Iranmanesh and Dr. Christian
Toso, both of Geneva University Hospital in Switzerland, in a
joint email to Reuters Health.
It is also associated with a safe risk profile and a
well-maintained quality of life, they reported online July 8 in
JAMA.
Their intermediate-risk criteria were age above 55, biliary
pancreatitis, or moderately elevated liver function tests.
High-risk markers are bilirubin above 4, ascending cholangitis,
common duct stones on ultrasound, or a common duct diameter >6
mm with a mildly elevated bilirubin, the authors say.
In their trial, patients with acute cholecystitis and
intermediate risk were randomized to either cholecystectomy and
intraoperative cholangiography (IOC) within 48 hours of
admission, with intraoperative or postoperative ERCP only if
necessary, or to endoscopic ultrasound (EUS) or magnetic
resonance cholangiopancreatography (MRCP) with ERCP if needed,
followed by cholecystectomy and IOC (i.e., the control group).
Excluded were patients with sepsis, lipase values three
times normal, CT evidence of pancreatitis, previous surgery
precluding ERCP, contraindications to MRCP, or inability to
consent to participation in the study.
After assessing 151 patients for eligibility, 51 were
excluded, and 50 were randomized to each group. Three patients
in the cholecystectomy-first group did not receive the
intervention. Two had contraindications to anesthesia and one
had acute pancreatitis. Two patients in the control group did
not have surgery due to the findings of alternate diagnoses for
their abnormal liver function studies.
The two cohorts were similar in age, sex distribution, body
mass index, American Society of Anesthesiologists' score, and
laboratory values.
The median hospital stay was five days in the surgery-first
group vs. eight days in controls (p<0.001).
Dr. Nicholas Alexakis, a surgeon at the University of Athens
Medical School in Greece who has done research on this topic,
told Reuters Health this was a well-conducted randomized
clinical trial from a reputable center. In his opinion, however,
"the primary end points should be successful CBD clearance,
morbidity and mortality and number of additional procedures
needed, and not hospital stay."
Patients in the control group had 71 total EUS, MRCP, and
ERCP studies vs. 25 in those who had surgery first (p<0.001).
No patient in either group underwent surgical common duct
exploration.
Operative times, conversions from laparoscopy to laparotomy,
reoperations, and readmissions were similar in the two groups.
Common duct stones were found in 11 patients who had surgery
first - 10 on IOC and one on postoperative ERCP. The 10
identified on IOC had postop EUS exams. According to Drs.
Iranmanesh and Toso, approximately 21% of CBD stones
spontaneously migrate to the duodenum. They said, "EUS was
performed postoperatively in patients with an IOC showing CBD
stones to confirm the diagnosis and avoid unnecessary ERCPs."
Ten control patients had common duct stones, discovered in
eight on preoperative EUS and in two on IOC. The eight patients
with stones found on EUS had successful preoperative ERCPs. One
of the other two patients had intraoperative irrigation of the
common duct which flushed the stone and the other had a
postoperative ERCP.
The incidence and severity of complications were similar in
both groups, as were postoperative quality of life scores.
The authors did not do a formal cost analysis but pointed
out that shorter hospital stays and fewer common duct
investigations suggests considerably lower costs with a strategy
of surgery plus IOC first.
At the authors' institution, IOCs are performed on all
patients undergoing cholecystectomy regardless of the risk of
CBD stone. They feel that IOC helps identify CBD stones,
interval migration, and minimizing and identifying iatrogenic
bile duct lesions.
Dr. Alexakis, however, does not advocate routine IOC. "IOC
increases operating time and cost," he said. "The interpretation
is subjective and can have false positive and false negative
results."
At his hospital, patients with an intermediate risk of CBD
stones have MRCP before surgery and ERCP if stones are found.
"When we launched the trial, the standard management of
patients with an intermediate risk of CBD stones was to perform
systematic preoperative CBD assessment," said the corresponding
authors. "We felt that this strategy was not optimal and
therefore decided to design this trial. Our team now treats
these patients using a 'cholecystectomy first' strategy."
SOURCE: http://bit.ly/1stPmP0
JAMA 2014.
|